Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


4D pharma announces the presentation of a late-breaking poster on data from Part A of the Phase I/II trial of MRx-4DP0004 for the treatment of asthma. The poster is being presented at the 2022 American Thoracic Society (ATS) International Conference, May 13-18, 2022 in San Francisco, CA, US.
Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study. Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT)
4D pharma today announces US FDA clearance of its IND applications for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease. IND clearance marks the expansion of 4D pharma’s clinical-stage pipeline of single strain Live Biotherapeutics into neurology, and the first US FDA IND clearance for a Live Biotherapeutic for Parkinson’s disease.